Mirna-Based Therapies: Strategies and Delivery Platforms for Oligonucleotide and Non-Oligonucleotide Agents
Year: 2014
Type: review
Abstract: The discovery of miRNAs as important regulatory agents for gene expression has expanded the therapeutic opportunities for oligonucleotides. In contrast to siRNA, miRNA-targeted therapy is able to influence not only a single gene, but entire cellular pathways or processes. It is possible to supplement downregulated or non-functional miRNAs by synthetic oligonucleotides, as well as alleviating effects caused by overexpression of malignant miRNAs through artificial antagonists, either oligonucleotides or small molecules. Chemical oligonucleotide modifications together with an efficient delivery system seem to be mandatory for successful therapeutic application. While miRNA-based therapy benefits from the decades of research spent on other therapeutic oligonucleotides, there are some specific challenges associated with miRNA therapy, mainly caused by the short target sequence. The current status and recent progress of miRNA-targeted therapeutics is described and future challenges and potential applications in treatment of cancer and viral infections are discussed.
Source: Future Medicinal Chemistry
DOI: 10.4155/fmc.14.116
Authors: Volker Baumann, Johannes Winkler
Institution: University of Vienna
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: green
Estimated APC paid: $2,805
Funder: Austrian Science Fund
OpenAlex ID: W2059310361
